跳至主要内容
临床试验/NCT03242824
NCT03242824已完成2 期

MC167B: Pilot Study Investigating the Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma

Mayo Clinic1 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2017年9月29日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Mayo Clinic
入组人数
21
试验地点
1
主要终点
Proportion of Participants With Progression-free Survival

研究概览

简要总结

This proposal is for a pilot study comparing volumes of 18F-DOPA-PET avidity with contrast enhancement and T2 FLAIR on MRI. Investigators then plan to compare patterns of failure with target volumes, pre-treatment MRI changes and pre-treatment 18F-DOPA-PET.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

18F-DOPA PET

Experimental

Patients will receive 18FDOPA-PET for radiation treatment planning

干预措施: Fluorine F 18 Fluorodopa (Drug)

18F-DOPA PET

Experimental

Patients will receive 18FDOPA-PET for radiation treatment planning

干预措施: Intensity-Modulated Radiation Therapy (Radiation)

18F-DOPA PET

Experimental

Patients will receive 18FDOPA-PET for radiation treatment planning

干预措施: Positron Emission Tomography (Procedure)

结局指标

主要结局

Proportion of Participants With Progression-free Survival

时间窗: up to 3 months

measured by reviewing 18F-DOPA-PET and conventional MRI with historical controls

次要结局

  • Quality of Life Brief Fatigue Index (BFI) Change From Baseline(Baseline and 3 months)
  • Overall Survival(From date of diagnosis to date of death from any cause censoring patients alive at their last follow-up; patients assessed for survival up to 2 years from randomization. Diagnosis date occurs prior to randomization by up to 15 years)
  • Toxicity, Rate of Grade 3 or Higher Treatment Related to Toxicities(up to 2 years)
  • Re-operative Count(up to 2 years)
  • Quality of Life MDASI-BT Change From Baseline(Baseline and 3 months)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验